HomeCompareLEVOX vs ABBV

LEVOX vs ABBV: Dividend Comparison 2026

LEVOX yields 43.96% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LEVOX wins by $184.7K in total portfolio value
10 years
LEVOX
LEVOX
● Live price
43.96%
Share price
$12.78
Annual div
$5.62
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$287.1K
Annual income
$52,433.30
Full LEVOX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LEVOX vs ABBV

📍 LEVOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLEVOXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LEVOX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LEVOX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LEVOX
Annual income on $10K today (after 15% tax)
$3,736.76/yr
After 10yr DRIP, annual income (after tax)
$44,568.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LEVOX beats the other by $23,512.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LEVOX + ABBV for your $10,000?

LEVOX: 50%ABBV: 50%
100% ABBV50/50100% LEVOX
Portfolio after 10yr
$194.7K
Annual income
$38,602.53/yr
Blended yield
19.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LEVOX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LEVOX buys
0
ABBV buys
0
No recent congressional trades found for LEVOX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLEVOXABBV
Forward yield43.96%3.06%
Annual dividend / share$5.62$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$287.1K$102.3K
Annual income after 10y$52,433.30$24,771.77
Total dividends collected$221.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LEVOX vs ABBV ($10,000, DRIP)

YearLEVOX PortfolioLEVOX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,096$4,396.19$11,550$430.00+$3.5KLEVOX
2$22,355$6,202.40$13,472$627.96+$8.9KLEVOX
3$32,504$8,584.00$15,906$926.08+$16.6KLEVOX
4$46,444$11,664.46$19,071$1,382.55+$27.4KLEVOX
5$65,272$15,576.52$23,302$2,095.81+$42.0KLEVOX
6$90,299$20,458.86$29,150$3,237.93+$61.1KLEVOX
7$123,072$26,452.01$37,536$5,121.41+$85.5KLEVOX
8$165,381$33,693.84$50,079$8,338.38+$115.3KLEVOX
9$219,273$42,314.83$69,753$14,065.80+$149.5KLEVOX
10$287,055$52,433.30$102,337$24,771.77+$184.7KLEVOX

LEVOX vs ABBV: Complete Analysis 2026

LEVOXStock

The investment seeks long-term capital appreciation. The Portfolio invests primarily in equity securities, principally common stocks, of U.S. companies of any market capitalization. The Portfolio has a concentrated portfolio of investments, typically investing in 15 to 35 companies with market capitalizations generally greater than $350 million. The Portfolio seeks to outperform broad-based securities market indices, such as the S&P 500® Index, the Russell 1000® Index and the Russell 3000® Index. Under normal circumstances, the Portfolio invests at least 80% of its assets in equity securities of U.S. companies. The fund is non-diversified.

Full LEVOX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LEVOX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LEVOX vs SCHDLEVOX vs JEPILEVOX vs OLEVOX vs KOLEVOX vs MAINLEVOX vs JNJLEVOX vs MRKLEVOX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.